Change in Pediatric Functional Classification During Treatment and Morbidity and Mortality in Children with Pulmonary

Emily Morell Balkin1, Emma D Olson2, Laura Robertson3

  • 1Department of Pediatrics, UCSF Benioff Children's Hospital, University of California San Francisco, San Francisco, CA, USA.

Pediatric Cardiology
|February 5, 2016
PubMed

Insights

Pediatric Functional Class (FC) at diagnosis does not predict outcomes in children with pulmonary hypertension (PH). However, improved FC over time and at the last visit are linked to better survival and reduced morbidity in PH patients.

Area of Science:

  • Pediatric Cardiology
  • Pulmonary Hypertension Research
  • Clinical Outcomes Assessment

Background:

  • Outcomes for pediatric pulmonary hypertension (PH) remain poor despite therapeutic advancements.
  • A validated functional classification system is crucial for assessing disease severity and treatment response in children.

Purpose of the Study:

  • To evaluate the validity of a pediatric-specific functional classification system for pulmonary hypertension (PH).
  • To assess the association of Pediatric Functional Class (FC) with mortality and morbidity in a diverse pediatric PH population.

Main Methods:

  • Retrospective single-center study of 65 infants and children with PH.
  • Analysis of Pediatric Functional Class (FC) at diagnosis, last visit, and change over time.
  • Univariate, time-to-event, and multivariate regression analyses to correlate FC with outcomes.

Main Results:

  • FC at diagnosis was not significantly associated with survival (p = 0.22).
  • Higher FC at the last visit (p < 0.001) and improvement in FC over time (HR 2.3, p = 0.0003) were significantly associated with mortality.
  • Higher FC at last visit correlated with increased ICU hospitalization, cardiac arrest, and syncope.

Conclusions:

  • Pediatric Functional Class (FC) at diagnosis does not predict mortality in children with PH.
  • Response to therapy, indicated by change in FC and FC at last visit, is associated with morbidity and mortality.
  • Multicenter prospective studies are needed to further validate these findings for pediatric PH management.

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
827
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
327
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
574
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
458
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
369
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
693